The global Rituxan Rituximab drug market is expected to grow at a significant CAGR during the forecast period. The major factor contributing to the growth of the global Rituxan Rituximab drug market include the rising prevalence of chronic disorders such as rheumatoid arthritis, chronic lymphocytic leukaemia, and many more. 

Rituximab is the first approved humanized monoclonal antibody intended to treat B-cell malignancies by complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity. Rituxan (Rituximab) is the prescription drug intended to treat various chronic and serious disorders including rheumatoid arthritis, chronic lymphocytic leukaemia, Non-Hodgkin’s Lymphoma, Granulomatosis with polyangiitis and microscopic polyangiitis, and Pemphigus Vulgaris. Rituximab is a branded drug owned by Hoffmann-La-Roche and was approved by US FDA in November 1997.

There are several biosimilars of Rituxan (Rituximab) launched after the success of the drug. For instance, in December 2020, RIABNI (rituximab-are) a biosimilar of Rituxan (Rituximab) by Amgen Inc. was approved by the US Food and Drug Administration for the treatment of rheumatoid arthritis, chronic lymphocytic leukaemia, Non-Hodgkin’s Lymphoma, Granulomatosis with polyangiitis and microscopic polyangiitis, and Pemphigus Vulgaris and is available in the US from January 2021.

Hoffmann-La-Roche is developing a new line of therapies for the treatment of rare diseases with a combination of Rituxan (Rituximab). For instance, in September 2019, Rituximab was approved by the US Food and Drug Administration for the treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in pediatric patients (2 years or older), in combination with glucocorticoids.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Application

o By Distribution Channel

• Regions covered-

o North America

o Europe

o Asia Pacific

o Rest of the World

• Competitive Landscape- Hoffmann-La-Roche

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Rituxan Rituximab Drug Market by Segments

By Application

• Rheumatoid arthritis 
• Chronic lymphocytic leukaemia 
• Non-Hodgkin’s Lymphoma
• Granulomatosis with polyangiitis and microscopic polyangiitis
• Pemphigus Vulgaris

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Rituxan Rituximab Drug Market by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa